GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.

Bristol-Myers Squibb has handed back rights to a TIGIT drug partnered with Agenus, ending an alliance that could have been worth up to $1.56 billion to the biotech. Agenus revealed BMS' decision ...

• Corporate actions are actions taken by a company that impact the shareholders’ value directly. It is an event that brings material changes to a company and affects its stakeholders ...